Black Friday Get Elite for just $149.00 Claim Now

VivoSim Labs Secures Seven-Figure Pharmaceutical Testing Agreement and Raises Fiscal 2027 Revenue Growth Expectations

By Fiona Craig | November 19, 2026, 10:27 AM

VivoSim Labs, Inc. (NASDAQ:VIVS) announced a seven-figure agreement with a top-10 global pharmaceutical company for its NAMkind human tissue testing services, prompting the company to forecast fiscal 2027 revenue growth above its previous guidance of more than 500%.

The agreement covers liver and intestinal toxicology testing using VivoSim’s three-dimensional human cellular models. Work has already commenced, with revenue expected to be recognised during the company’s third and fourth fiscal quarters, ending December 31, 2026, and March 31, 2027, respectively.

VivoSim said the agreement represents a transition from initial scientific evaluation to paid testing on active drug development programmes. The company expects the pharmaceutical customer to incorporate NAMkind testing into its regular preclinical development processes following completion of the current programme.

The customer was not identified, and VivoSim did not disclose the precise contract value beyond describing it as a seven-figure agreement.

Agreement Expected to Push Revenue Growth Above 500%

VivoSim previously forecast fiscal 2027 revenue growth exceeding 500% in guidance issued on July 15, 2026.

The company now expects to surpass that target following the latest agreement, although it has not provided a revised numerical growth forecast.

Its quarterly report for the period ended September 30, 2026, filed on November 12, showed growth across both its liver and intestinal toxicology businesses.

Management attributed the expansion to demand from large pharmaceutical companies and smaller biotechnology customers.

VivoSim expects additional customers to progress from initial evaluations to incorporating its testing services into routine drug development activities.

Keith Murphy, Executive Chairman of VivoSim Labs, said:

“In July we told shareholders revenue would grow more than 500% this fiscal year. The quarterly report we filed last week shows both toxicology businesses growing, and this agreement on its own is expected to take us past that number.”

Murphy added that the company anticipates recurring testing work from the pharmaceutical customer following the initial programme, with other major customers progressing through similar evaluation processes.

NAMkind Testing Targets Drug Safety Assessment

VivoSim’s NAMkind platform uses three-dimensional models developed from primary human liver and intestinal cells to assess drug safety and potential toxicity.

The models can be exposed repeatedly to compounds over several weeks, allowing researchers to examine biological responses during preclinical development.

According to VivoSim, its NAMkind Liver model demonstrated 91% accuracy, 90% sensitivity and 95% specificity in predicting drug-induced liver injury across a clinical dataset of 92 small-molecule compounds.

The company contrasted these findings with traditional animal-based methods, which it said typically identify between 50% and 65% of compounds associated with liver toxicity.

VivoSim also presented additional research involving antibody-drug conjugates at EUROTOX 2026 in September.

The company highlighted regulatory developments supporting the use of non-animal testing methods, including a September 2026 US Food and Drug Administration rule clarifying that such approaches may be used, where appropriate, in evaluating the safety of drugs and biological products.

VivoSim Expands Testing Capabilities and Research Partnerships

The pharmaceutical agreement follows several recent developments in VivoSim’s service offering.

On October 21, the company introduced efficacy testing using disease models developed from patient-donated liver and intestinal cells. The expanded services include pharmacodynamic analysis and biomarker profiling.

On November 3, VivoSim announced a collaboration with Chemveda Life Sciences involving the testing of AI-designed compounds using human tissue models.

Initial programmes under that collaboration are expected to begin during the current quarter.

VivoSim scientists are also presenting research at the American College of Toxicology’s 47th Annual Meeting in San Antonio, Texas, focusing on the potential of its multiparametric testing approach to help assess clinical development risks.

The company’s management is using the conference to engage with existing and prospective pharmaceutical partners.

VivoSim Expects Further Adoption by Pharmaceutical Customers

Tony Lialin, Chief Commercial Officer of VivoSim Labs, said the company was seeing increased demand across both of its toxicology service lines.

“Both toxicology service lines grew in the September quarter, with orders from large pharmaceutical companies and from smaller biotechs,” Lialin said.

“A large customer comes in through an evaluation, then a paid program, then its standing workflow. This Customer is at the second step, and we have others at the first.”

The latest agreement provides VivoSim with additional contracted testing work and supports management’s expectations for stronger fiscal 2027 revenue growth.

However, the anticipated transition to recurring testing arrangements remains dependent on customer adoption following the initial programme.

VivoSim will recognise revenue from the current agreement during the second half of its fiscal year, while continuing to develop its human tissue testing services and expand relationships with pharmaceutical and biotechnology customers.

VivoSim Labs stock price

Mentioned In This Article

Latest News

Nov-19
Nov-19
Nov-16
Nov-12
Nov-10
Nov-03
Oct-21
Oct-07
Sep-16
Sep-01
Aug-12
Aug-06
Jul-21
Jul-21
Jul-16